None
Conditions
Interventions
Older age-group:0.1 µg/kg of sufentanil + 0.16 mg/kg of remimazolam
Non-elderly group:0.1 µg/kg of sufentanil + 0.22 mg/kg of remimazolam
Sponsors
The First People's Hospital of Linping District, Hangzhou City
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age 18 - 80 years old; 2. ASA I-II; 3. Surgery under general anesthesia; 4. Body Mass Index (BMI) 18 - 30 kg/m^2; 5. Signed informed consent form, able to accept the experimental methods, and voluntarily chosen as a participant.
Exclusion criteria
Exclusion criteria: 1. Emergency surgery patients; 2. Those who are allergic to or have contraindications to ramazolone benzenesulfonate; 3. Those with preoperative consciousness disorders, or those who have been using analgesics, psychotropic drugs (such as opioids, NSAIDs, sedatives, antidepressants) due to chronic pain for a long time, and those with a history of alcohol abuse; 4. Those who have used sedative, antiemetic or antiitching drugs within 24 hours before the surgery, or those who have taken monoamine oxidase inhibitors or antidepressants within the last 15 days; 5. Those who are expected to have difficulty with tracheal intubation; 6. Those with liver or kidney dysfunction, gastrointestinal ulcers or bleeding tendencies; 7. Those who do not consent to participate or have already participated in other drug clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| EEG dual frequency index;Modified Alertness/Sedation Score; | — |
Secondary
| Measure | Time frame |
|---|---|
| Heart rate;Incidence of respiratory depression;Other adverse reactions (incidence rates of flexion, hiccups, choking cough, etc.); | — |
Countries
China
Contacts
Public ContactJunli Zheng
The First People's Hospital of Linping District, Hangzhou City
Outcome results
None listed